Overall Goal. Clinical Conversations: Nursing Care for Patients With Multiple Myeloma.

Slides:



Advertisements
Similar presentations
Shafiepour,mohsen MD. Kerman university of medical sciences.
Advertisements

Supportive Care in Multiple Myeloma
PLASMA CELL DYSCRASIAS Monoclonal gammopathy of uncertain significance (MGUS)  Idiopathic  Associated with other diseases (autoimmune, infectious, non-heme.
Drugs Used in the Treatment of Multiple Myeloma Myeloma Canada National Conference 2011-September-24 Toronto, Ontario Carlo De Angelis, RPh, PharmD Clinical.
Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach for Proteasome-Inhibitor Based Therapy in Waldenstrom’s.
Bisphosphonates effectively manage bone complications from cancer
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Justin A. Crocker.  1 of the monoclonal gammopathies  Neoplastic proliferation of immunoglobulin producing plasma cells (single clone), often resulting.
CINVForum Web-symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients Survey on CINV – Results Base: 168 registered physicians.
Plasma cell dyscrasias. Multiple Myeloma By Dr. Muna A. Kashmool.
Osteonecrosis of the Jaws in Myeloma BRIAN G.M. DURIE, M.D., Michael Katz, Jason McCoy, MS and John Crowley, PhD Hematology/Oncology, Cedars-Sinai Outpatient.
Evaluating the Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Patients with Multiple Myeloma: Results of the Medical Research Council.
REGULATORY HISTORY of ZOMETA and AREDIA JAW OSTEONECROSIS (ONJ) Oncologic Drug Advisory Committee March 4, 2005 Nancy S. Scher, M.D.
AIMING FOR EXCELLENCE IN OUTCOMES IN HAEMATOLOGIC MALIGNANCIES Taking a Deeper Approach to Multiple Myeloma Treatment UK/NP/1508/0047b(1) April 2016 A.
Sarah Kunin, MD Princeton Baptist Medical Center Baptist Health Systems Alabama Multiple Myeloma: Treatment with Bisphosphonates.
Multiple Myeloma: Is it now a curable disease?
VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.
Future Strategies for Myeloma
Taylor Butler, PharmD, BCOP Decentralized Clinical Pharmacist
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Recommendations for Catheter-to-Vein Ratio
The Nurse’s Role in Inflammatory Bowel Disease
The Nurse View: Management of Pancreatic Cancer
Mateos MV et al. Proc ASH 2013;Abstract 403.
The Nurse View.
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
NOACs for Cancer-Associated Thrombosis:
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Making Decisions With Your Osteoarthritis Patients
Challenging Cases in Multiple Myeloma Panel Discussion
NOACs In Long-term VTE Treatment: A State Of The Art Review
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Biomarker-Driven Management of Sepsis and Antibiotics Evidence and Perspectives.
Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.
Treating Transplant-Ineligible Patients With Multiple Myeloma
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
Selecting MM Therapy in Patients With Comorbidities
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Enhancing Patient Care in Advanced NSCLC Through Clinician-Patient Partnership.
Patients with osteoporosis may experience oral changes, such as:
The Nurse View: Best Practices in Multiple Myeloma
Niesvizky R et al. Proc ASH 2010;Abstract 619.
A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.
Time to Take Gout Seriously
Updates in Preventing Skeletal-Related Events in Multiple Myeloma
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Optimizing Frontline Care for Older Patients With Multiple Myeloma
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Approaches in Newly Diagnosed Multiple Myeloma: When and What
Staying Abreast of Best Practices Across the Clinical Continuum
Managing Multiple Myeloma in the Elderly
Oncology Nursing Development in Singapore:
Factor Xa Inhibitors in PAD
Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
The Role of Maintenance Therapy in Multiple Myeloma
The Changing Field of Melanoma: Ipilimumab.
Response to Carfilzomib Therapy
References: Oncological Surgyery: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment.
How I treat cancer-associated venous thromboembolism
Program Goals Background: Anticoagulation in Patients With VTE.
Factor Xa Inhibitors in Coronary Artery Disease
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.
Renal Function and Myeloma Therapeutics
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Navigating the Journey
Presentation transcript:

Clinical Conversations: Nursing Care for Patients With Multiple Myeloma

Overall Goal

Multiple Myeloma Epidemiology in the United States

Introduction

Complications of Myeloma: Kidney Disease

Complications of Myeloma: Bone Disease and Hypercalcemia

Complications of Myeloma: Venous Thromboembolism (VTE)

Case Study

Initial Diagnostic Evaluationa-c

Diagnostic Criteria

Electrophoresis

Types of M-Protein

Special Types of Myeloma

Tests Useful in Some Circumstances

Diagnostic Criteria for Symptomatic Multiple Myeloma

MGUS

Case Study (cont)

Agents for Multiple Myeloma

Using Bortezomib

Principal Side Effects of Bortezomiba-d

Peripheral Neuropathy and Myeloma

Symptom Control for Peripheral Neuropathy

NCCN: Preferred Regimens for Myeloma Induction Therapy

Principal Side Effects of IMiDs

Side Effects With Bortezomib

Principal Side Effects of IMiDs (cont)

Preventing VTE With IMiDs

Important Risk Factors for VTE

Bone Destruction in Myeloma

Osteonecrosis of the Jaw (ONJ)

ASCO® Guidelines: Use of Bisphosphonates in Myeloma

Role of Nurses in Caring for Myeloma Patients

Thank you for participating in this Medscape Oncology CE activity.

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.